Edition:
United States

Synthetic Biologics Inc (SYN.A)

SYN.A on American Stock Exchange

1.78USD
4:02pm EDT
Change (% chg)

$-0.01 (-0.56%)
Prev Close
$1.79
Open
$1.78
Day's High
$1.80
Day's Low
$1.73
Volume
24,369
Avg. Vol
119,288
52-wk High
$3.44
52-wk Low
$0.93

SYN.A

Chart for SYN.A

About

Synthetic Biologics, Inc. is a clinical-stage company. The Company is engaged in developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases. The Company's lead product candidates in Phase II development are SYN-010, which is intended to reduce the impact of methane-producing organisms in the... (more)

Overall

Beta: 1.38
Market Cap(Mil.): $163.37
Shares Outstanding(Mil.): 91.27
Dividend: --
Yield (%): --

Financials

  SYN.A Industry Sector
P/E (TTM): -- 42.74 36.62
EPS (TTM): -0.51 -- --
ROI: -1,785.55 -9.63 14.52
ROE: -1,822.75 -9.94 15.68

BRIEF-Synthetic Biologics gets European, U.S. composition of matter patents for Ribaxamase

* Synthetic Biologics announces granting of European and U.S. composition of matter patents for Ribaxamase Source text for Eikon: Further company coverage:

Jul 12 2016

BRIEF-Synthetic Biologics receives USAN approval for generic name ribaxamase for SYN-004

* Synthetic Biologics receives USAN approval for generic name ribaxamase for Phase 2 drug candidate SYN-004

Jul 07 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : MacroRisk Analytics/EconomicInvestor
$25.00
Provider : ValuEngine, Inc.
$25.00
Provider : S&P Capital IQ Quantitative Report
$115.00
Provider : Pechala's Reports
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.